CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 36 enrolled
Drug / intervention
Lee Silverman Voice Treatment +2 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03700684
NCT03700684N/ACompleted

A Comparison of Two Forms of Intensive Voice Treatment for Parkinson's Disease

University of Massachusetts, Amherst·interventional·Posted Oct 9, 2018·Updated May 30, 2023

In Brief

A clinical study evaluating Lee Silverman Voice Treatment, SpeechVive, and 1 other intervention for Idiopathic Parkinson Disease. Completed, enrolled 36 participants across 2 sites.

Detailed Summary

This study addresses several issues related to the clinical management of speech and voice disorders associated with Parkinson's disease. Two behavioral treatment programs, Lee Silverman Voice Treatment and SpeechVive, are assessed in their ability to improve communication in persons with Parkinson's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 9, 2018
Enrollment StartSep 19, 2018
Primary CompletionMar 15, 2020
Study CompletionNov 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.7 years ago

Interventions

Lee Silverman Voice Treatmentbehavioral

Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.

SpeechVivedevice

Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.

Controlbehavioral

Persons assigned to the non-treatment control group will not participate in voice treatment.